Abstract
Aims Dormant coronary collaterals are highly prevalent and clinically beneficial in cases of coronary occlusion. However, the magnitude of myocardial perfusion provided by immediate coronary collateral recruitment during acute occlusion is unknown. The aim of this study was to quantify collateral myocardial perfusion during balloon occlusion in patients with coronary artery disease (CAD).
Methods and results Patients without angiographically visible collaterals undergoing elective percutaneous transluminal coronary angioplasty (PTCA) to a single epicardial vessel underwent two scans with 99mTc-sestamibi myocardial perfusion single-photon emission computed tomography (SPECT). All subjects underwent at least three minutes of angiographically verified complete balloon occlusion, at which time an intravenous injection of the radiotracer was administered, followed by SPECT imaging. A second radiotracer injection followed by SPECT imaging was performed 24 hours after PTCA.
The study included 22 patients (median [interquartile range] age 68 [54-72] years, 10 (45%) female). The perfusion defect extent was 19 [11–38] % of the LV, and the collateral perfusion at rest was 64 [58-67]% of normal.
Conclusion This is the first study to describe the magnitude of short-term changes in coronary microvascular collateral perfusion in patients with CAD. On average, despite coronary occlusion and an absence of angiographically visible collateral vessels, collaterals provided more than half of the normal perfusion.
Graphical abstractDormant collaterals are highly prevalent but the magnitude of myocardial perfusion provided by immediate coronary collateral recruitment during acute occlusion in humans is unknown. Patients without angiographically visible collaterals underwent intravenous injection with 99mTc-sestamibi during coronary balloon inflation followed by SPECT imaging. A control scan was performed 24 hours later..Median collateral perfusion during coronary occlusion was 64% of normal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the IRB (Investigational Review Board) at Charleston Area Medical Center (CAMC) in Charleston, WV prior to study initiation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor adjustments to data analysis and text.
Data Availability
Data can be made available upon reasonable request to the corresponding author.
